Our research suggests that CCL19, SELL and VCAM-1 may promote inflammatory cell infiltration and nerve injury through synergistic effects in the pathology of Bell’s palsy, and although there is no clear signaling axis linking the three indirect crosstalk, their joint role in immune cell recruitment and vascular endothelial activation may be key to the onset and progression of the disease [25,26,27]. This evidence concerns the gene SELL and Bell's palsy.